Clinical Trials on Contrast Agent in Hungary

Total 6 results

Bayer

Recruiting

A Study to Learn How Gadoquatrane Moves Into, Through, and Out of the Body and How Safe it is in Children (From Birth to <18 Years), Who Will Undergo a Contrast Enhanced MRI (Quanti Pediatric)

Children | Contrast Enhancement in Magnetic Resonance Imaging

United States, Japan, China, Canada, Czechia, Poland, Argentina, Bulgaria, Belgium, Germany, Sweden, Hungary, Italy
Bayer

Recruiting

A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Known or Suspected Brain or Spinal Cord-related Problems (Quanti CNS)

Contrast Enhancement in Magnetic Resonance Imaging | Central Nervous System Pathology

France, Turkey, Czechia, China, Japan, Korea, Republic of, United Kingdom, Italy, United States, Hungary, Argentina, Bulgaria, Canada, Germany, Sweden
Bayer

Recruiting

A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Any Known or Suspected Problems of the Body (Except Brain or Spinal Cord-related Problems) (Quanti OBR)

Contrast Enhancement in Magnetic Resonance Imaging | Non-central Nervous System Pathology

United States, Sweden, Japan, Czechia, China, Hungary, Poland, Italy, United Kingdom, Turkey, Korea, Republic of, Germany, Taiwan, France, Argentina, Bulgaria, Canada
Novartis Pharmaceuticals

Completed

Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias

Parkinson Disease | Parkinsonian Disorders | Movement Disorders | Dyskinesias | Anti-Dyskinesia Agents

Spain, United States, Austria, Switzerland, France, Germany, Italy, Canada, Hungary, Slovakia
Novartis Pharmaceuticals

Completed

Evaluation of the Efficacy and Safety of Modified Release AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias

Parkinson Disease | Parkinsonian Disorders | Movement Disorders | Dyskinesias | Anti-Dyskinesia Agents

Spain, United States, Austria, Switzerland, France, Germany, Italy, Hungary, Canada, Slovakia
Eli Lilly and Company

Active, not recruiting

A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer) (CYCLONE 3)

Urogenital Neoplasms | Prostatic Neoplasms | Neoplasm Metastasis | Enzyme Inhibitors | Antineoplastic Agents | Hormones | Physiological Effects of Drugs | Antineoplastic Agents, Hormonal | Androgens | Hormones, Hormone Substitutes, and Hormone Antagonists | Abiraterone Acetate | Steroid Synthesis Inhibitors | Cytochrome... and other conditions

China, Canada, France, United States, Australia, Czechia, Hungary, Spain, Germany, Japan, Taiwan, Netherlands, Turkey, Mexico, Belgium, Korea, Republic of, Argentina, Romania, United Kingdom, Italy, Israel, Brazil, Poland, Greece

Clinical Trials on Contrast Agent in Hungary

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ukraine

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations